clinical trial · NCT06707480
Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
CorMedix·—·available
Catheter-related Bloodstream InfectionTaurolidine and Heparin
brief summary
The EAP for DefenCath is designed to provide access to a broader population of adult and pediatric patients using catheters for various serious medical conditions. A key aspect of this EAP is its focus on individuals who, due to their unique clinical circumstances, are either ineligible for participation in ongoing clinical trials or do not meet the criteria outlined in the current approved FDA label for DefenCath.
started
—
primary completion
—
completion
—
last updated
Nov 27, 2024
official title
Expanded Access Program to Provide Access to Defencath® for Adult and Pediatric Patients Using a Catheter to Prevent Central Line-Associated Bloodstream Infections (CLABSIs)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol